Skip to main content
OpenTrials
Completed

NCT Number: NCT03705832

Ginger's Therapeutic Potential in Asthma

This is a randomized, double blind, placebo controlled study to study whether there are potential benefits of consuming ginger by individuals with asthma.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Columbia University Asthma Center

New York, 10032, United States

About this study

Presently an estimated 25.9 million Americans suffer from asthma and over half have at least one asthma attack per year. Recent studies found that 60% of moderate asthmatics and 70% of severe asthmatics report using complementary and alternative medicine (CAM) to self-treat their asthma symptoms.The exact mechanism of action of these agents is unclear but may involve attenuation of allergic response, anti-inflammatory and antioxidant effects, and/or direct effects on airway smooth muscle which are responsible for airway narrowing in asthma.

Studies done in mouse models of asthma and directly on airway smooth muscle cells demonstrate that ginger blocks one of the critical inflammatory pathways in asthma and thus leads to reduced airway inflammation and relaxation of airway smooth muscle. Clinical trials with chronic oral ginger therapy in humans have demonstrated safe consumption of 2 grams per day for 28 days with demonstrated anti-inflammatory effects in colon cancer and inflammatory bowel diseases. Thus, the investigators hypothesize that oral ginger at a dose of 2 grams per day will reduce airway inflammation and will reduce serum levels of asthma related inflammatory markers.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men or women age 18 or older;
  • Treatment with inhaled corticosteroids (ICS) +/- long acting β-agonists/long acting muscarinics and montelukast;
  • Physician diagnosed asthma;
  • Forced expiratory volume (FEV1) ≥60% of predicted
  • Methacholine PC(20) < 16 mg/ml if taking ICS and < 8mg/ml if not taking ICS at Visit 2.
  • Non-smoker (e.g., tobacco, e-cigarette, marijuana) for ≥1 yr.;
  • ≤10 pack-year smoking history;
  • Suboptimal control of asthma as determined by a score < 19 or less on the Asthma Control Test (ACT) at Screening Visit (Visit 1) and Randomization Visit (Visit 3).

Exclusion criteria

  • Other major chronic illnesses: Conditions which in the judgment of the study physician would interfere with participation in the study, e.g., non-skin cancer, uncontrolled diabetes mellitus, coronary artery disease, congestive heart failure, stroke, severe hypertension, renal failure, liver disorders, malabsorption disorders, immunodeficiency states, major neuropsychiatric disorder;
  • Cardiovascular problems: Myocardial infarction or stroke in last 3 months Uncontrolled hypertension Known aortic aneurysm
  • History of physician diagnosis of chronic bronchitis, emphysema or chronic obstructive pulmonary disease (COPD)
  • Medication use: Current consumption of ginger supplements, oral corticosteroid use within the past 6 weeks, use of an investigational treatment in the previous 30 days, known adverse reaction to ginger or ginger products;
  • Females of childbearing potential: Pregnant or lactating; participants of appropriate age who might be pregnant at the time of enrollment will be screened with urine pregnancy tests at each visit and cannot participate if pregnant. Participants must agree to use effective contraception during the trial.
  • Inability to perform acceptable and repeatable spirometry maneuvers throughout the test procedure.

Treatment and study plan

Ginger Extract

Drug

2gm Capsule of Ginger extract

Other names: Ginger

Placebo

Drug

Matching Placebo

Primary outcomes

  1. Change in Tolerance to Inhaled Methacholine

    Time frame: Baseline and Day 28

    A methacholine challenge test is a medical test used to assist in the diagnosis of asthma. The patient breathes in nebulized methacholine at gradually increasing doubling doses, starting with diluent only. Methacholine provokes bronchoconstriction, or narrowing of the airways via M3 receptors. The degree of narrowing can then be quantified by spirometry which is performed after inhalation of each dose. Methacholine provocation dose (PD)20 values will be used to measure any change in airway hyperresponsiveness.

  2. Change in Tolerance to Inhaled Methacholine

    Time frame: Baseline and Day 56

    A methacholine challenge test is a medical test used to assist in the diagnosis of asthma. The patient breathes in nebulized methacholine at gradually increasing doubling doses, starting with diluent only. Methacholine provokes bronchoconstriction, or narrowing of the airways via M3 receptors. The degree of narrowing can then be quantified by spirometry which is performed after inhalation of each dose. Methacholine provocation dose (PD20) values will be used to measure any change in airway hyperresponsiveness.

  3. Change in Fractional Exhaled Nitric Oxide (FeNO)

    Time frame: Baseline and Day 28

    Measure of markers of asthmatic lung inflammation

  4. Change in Fractional Exhaled Nitric Oxide (FeNO)

    Time frame: Baseline and Day 56

    Measure of markers of asthmatic lung inflammation

Secondary outcomes

  1. Change in Serum Cytokines

    Time frame: Baseline and Day 56

    Measure of markers of asthmatic lung inflammation

  2. Change in Eosinophilia

    Time frame: Baseline and Day 56

    Measure of markers of asthmatic lung inflammation

  3. Change in Score on the Asthma Control Test (ACT)

    Time frame: Baseline and Day 56

    Asthma symptom score will be measured with the Asthma Control Test at Visit 1, 2 and 5.This instrument, which has been validated for ages 12-84 years, is a 4-week recall questionnaire that addresses issues of asthma control, symptoms, and nocturnal awakenings. The scores range from 5 (poor control of asthma) to 25 (complete control of asthma), with higher scores reflecting greater asthma control. An ACT score >19 indicates well-controlled asthma.

  4. Change In Score on Juniper Mini-Asthma Specific Quality of Life (Mini AQLQ-J)

    Time frame: Baseline and Day 56

    This questionnaire consists of 15 items in 4 domains with a 2-week recall period. Scores range from 7-105, with higher scores indicating better quality of life.

Sponsors and collaborators

Lead sponsor

Emily DiMango, MD

Other

Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

Registry information

Acronym: GINGER

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Oct 15, 2018
Registry last updated
Mar 27, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.